

Lillian L Siu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4071295/lillian-l-siu-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

248
papers

15,438
citations

66
h-index

118
g-index

265
ext. papers

18,067
ext. citations

7.6
avg. IF

6.53
L-index

#	Paper	IF	Citations
248	Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.. <i>Oncologist</i> , 2022 , 27, e286-e293	5.7	0
247	Early detection of treatment futility in patients with metastatic colorectal cancer.. <i>Oncotarget</i> , 2022 , 13, 61-72	3.3	0
246	Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges.. <i>Science Advances</i> , 2022 , 8, eabi8618	14.3	4
245	Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. <i>Cancer Research Communications</i> , 2022 , 2, 39-48		0
244	Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 51	12.8	1
243	CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis. <i>Cell Genomics</i> , 2021 , 1, 100033		2
242	Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era. <i>European Journal of Cancer</i> , 2021 , 158, 85-98	7.5	1
241	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , 2021 , 165, 94-102	5.3	2
240	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa115	4.6	3
239	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology, The</i> , 2021 , 22, 298-301	21.7	9
238	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). <i>British Journal of Cancer</i> , 2021 , 124, 1543-1551	8.7	7
237	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021 , 20, 899-919	64.1	39
236	The Future of Clinical Trial Design in Oncology. <i>Cancer Discovery</i> , 2021 , 11, 822-837	24.4	6
235	Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. <i>Investigational New Drugs</i> , 2021 , 39, 1587-1597	4.3	4
234	Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4230-4244	12.9	9
233	Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>PLoS ONE</i> , 2021 , 16, e0253070	3.7	2
232	Using real-word data to evaluate the effects of broadening eligibility criteria in oncology trials. <i>Cancer Cell</i> , 2021 , 39, 750-752	24.3	1

231	Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	2
230	Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics. <i>Cancer Treatment Reviews</i> , 2021 , 92, 102125	14.4	5
229	The Day After COVID-19-Time to Rethink Oncology Clinical Research. <i>JAMA Oncology</i> , 2021 , 7, 23-24	13.4	5
228	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa122	4.6	5
227	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 980-988	9.7	7
226	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2117547	10.4	2
225	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021 , 12, 5137	17.4	5
224	Two-Target Quantitative PCR To Predict Library Composition for Shallow Shotgun Sequencing. <i>MSystems</i> , 2021 , 6, e0055221	7.6	2
223	HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2021 , 27, 5857-5868	12.9	6
222	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study 2021 , 9,		4
221	First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
220	Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. <i>Cancer</i> , 2021 , 127, 1620-1629	6.4	11
219	Innovation and Advances in Precision Medicine in Head and Neck Cancer 2021 , 355-373		0
218	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , 2020 , 38, 1774-1783	4.3	4
217	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , 2020 , 16, 1235-1243	3.6	16
216	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , 2020 , 126, 3426-3437	6.4	19
215	Circulating tumor DNA and liquid biopsy in oncology.. <i>Nature Cancer</i> , 2020 , 1, 276-290	15.4	123
214	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet, The</i> , 2020 , 395, 1078-1088	10	107

213	Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , 2020 , 9, 3015-3022	4.8	6
212	Molecular profiling for precision cancer therapies. <i>Genome Medicine</i> , 2020 , 12, 8	14.4	180
211	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , 2020 , 105, 104666	4.4	3
210	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020 , 9, 337	3.6	2
209	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 469-472	3.5	
208	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. <i>JAMA</i> , 2020 , 323, 100-107	13.4	34
207	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , 2020 , 144, 13-22	5.3	17
206	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020 , 126, 1550-1558	6.4	9
205	Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors 2020 , 8,		9
204	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020 , 26, 5329-5337	12.9	1
203	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020 , 26, 5153-5161	12.9	23
202	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.. <i>Nature Cancer</i> , 2020 , 1, 873-881	15.4	89
201	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors 2020 , 8,		12
200	A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020 , 13, 1178-1188	4.9	9
199	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020 , 126, 4936-4947	6.4	11
198	Increasing operational and scientific efficiency in clinical trials. <i>British Journal of Cancer</i> , 2020 , 123, 12078-12082	8.2	2
197	Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials. <i>Frontiers in Oncology</i> , 2019 , 9, 415	5.3	63
196	Designing circulating tumor DNA-based interventional clinical trials in oncology. <i>Genome Medicine</i> , 2019 , 11, 22	14.4	13

195	mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 346-352	3.5	21
194	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 655-663	9.7	35
193	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) 2019 , 7, 72		16
192	Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI853520. <i>Targeted Oncology</i> , 2019 , 14, 67-74	5	6
191	Utilization of tumor genomics in clinical practice: an international survey among ASCO members. <i>Future Oncology</i> , 2019 , 15, 2463-2470	3.6	6
190	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019 , 118, 112-120	7.5	5
189	PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>Journal of Hepatology</i> , 2019 , 70, e89	13.4	3
188	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz071	4.6	2
187	Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2542-2542	2.2	3
186	Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies. <i>Targeted Oncology</i> , 2019 , 14, 43-55	5	33
185	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019 , 125, 1341-1349	6.4	78
184	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , 2019 , 24, e518-e525	5.7	
183	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019 , 24, e146-e148	5.7	14
182	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 118-128	9.7	33
181	Outcomes of Older Patients (≥70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e140-e149	3.8	4
180	Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. <i>Journal of Molecular Diagnostics</i> , 2019 , 21, 261-273	5.1	17
179	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 195-203	13.4	141
178	Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort. <i>Head and Neck</i> , 2018 , 40, 2029-2042	4.2	14

177	A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. <i>Investigational New Drugs</i> , 2018 , 36, 1016-1025	4.3	24
176	Rational design and identification of immuno-oncology drug combinations. <i>European Journal of Cancer</i> , 2018 , 95, 38-51	7.5	7
175	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 73-79	3.8	16
174	Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. <i>International Journal of Cancer</i> , 2018 , 142, 57-65	7.5	20
173	Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , 2018 , 11, 65	3.7	12
172	Precision Medicine in Head and Neck Cancer: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2018 , 12, 1179554918779581	1.8	12
171	Lung cancer in never smokers from the Princess Margaret Cancer Centre. <i>Oncotarget</i> , 2018 , 9, 22559-22570	5.0	14
170	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 159-168	4.4	19
169	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement Summary. <i>Journal of Oncology Practice</i> , 2018 , 14, 167-171	3.1	11
168	Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. <i>Cancer Medicine</i> , 2018 , 7, 5478-5487	4.8	12
167	Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018 , 144, 71-79	3.9	22
166	A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. <i>Gynecologic Oncology</i> , 2017 , 141, 181-188	4.9	36
165	Giant Prolactinoma Presenting As a Base of Skull Tumor With Nasopharyngeal Extension: A Potential Diagnostic Pitfall in Neuroendocrine Lesions of the Base of Skull. <i>Head and Neck Pathology</i> , 2017 , 11, 537-540	3.3	2
164	Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball. <i>Cell</i> , 2017 , 168, 575-578	56.2	7
163	Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. <i>Clinical Cancer Research</i> , 2017 , 23, 4020-4026	12.9	9
162	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , 2017 , 123, 1409-1415	6.15	4
161	Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions. <i>New England Journal of Medicine</i> , 2017 , 376, 2006-2009	59.2	25
160	The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 39	5.4	7

159	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 220-226	13.4	48
158	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. <i>Targeted Oncology</i> , 2017 , 12, 775-785	5	46
157	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1606-1621	2.2	79
156	A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. <i>Cancer</i> , 2017 , 123, 4147-4157	6.4	50
155	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , 2017 , 8, 32918-32929	3.3	30
154	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. <i>Oncotarget</i> , 2017 , 8, 84659-84670	3.3	12
153	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , 2016 , 18, 128-36	8.1	66
152	Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. <i>Journal of Physical Education and Sports Management</i> , 2016 , 2, a001016	2.8	3
151	A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. <i>Oral Oncology</i> , 2016 , 59, 43-49	4.4	12
150	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 994-1002	4	1
149	Approaches to modernize the combination drug development paradigm. <i>Genome Medicine</i> , 2016 , 8, 115	14.4	42
148	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016 , 8, 109	14.4	149
147	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI?9041). <i>Investigational New Drugs</i> , 2016 , 34, 104-11	4.3	13
146	Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 858-67	12.9	13
145	A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 1348-55	12.9	37
144	PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. <i>JAMA Oncology</i> , 2016 , 2, 15-6	13.4	84
143	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , 2016 , 34, 575-83	4.3	6
142	Facilitating a culture of responsible and effective sharing of cancer genome data. <i>Nature Medicine</i> , 2016 , 22, 464-71	50.5	63

141	A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. <i>Investigational New Drugs</i> , 2016 , 34, 450-7	4.3	27
140	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 67, 174-182	7.5	46
139	Early phase clinical trials to identify optimal dosing and safety. <i>Molecular Oncology</i> , 2015 , 9, 997-1007	7.9	59
138	A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2793-802	1.9	24
137	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. <i>Journal of Clinical Oncology</i> , 2015 , 33, 836-45	2.2	279
136	Toward understanding and exploiting tumor heterogeneity. <i>Nature Medicine</i> , 2015 , 21, 846-53	50.5	441
135	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 996-1000	6.4	105
134	A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. <i>Cancer</i> , 2015 , 121, 1785-92	6.4	39
133	Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 1570-9	7.5	50
132	A multicenter phase 1 study of β -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 169-76	4.3	30
131	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , 2015 , 33, 652-63	4.3	32
130	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. <i>Oncologist</i> , 2015 , 20, 653-9	5.7	18
129	All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. <i>Cancer Discovery</i> , 2015 , 5, 1133-6	24.4	35
128	A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 1100-7	4.3	85
127	Cancer genomics: the challenge of drug accessibility. <i>Current Opinion in Oncology</i> , 2015 , 27, 250-7	4.2	11
126	Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT). <i>Investigational New Drugs</i> , 2015 , 33, 895-900	4.3	8
125	Cancer patients' acceptability of incorporating an epidemiology questionnaire within a clinical trial. <i>Clinical Trials</i> , 2015 , 12, 237-45	2.2	1
124	A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. <i>Clinical Cancer Research</i> , 2015 , 21, 68-76	12.9	56

123	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). <i>Investigational New Drugs</i> , 2014 , 32, 243-9	4.3	63
122	Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. <i>Cancer Discovery</i> , 2014 , 4, 527-37	24.4	67
121	Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014 , 32, 670-81	4.3	147
120	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2014 , 32, 1005-16	4.3	21
119	Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. <i>Cancer</i> , 2014 , 120, 181-9	6.4	14
118	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. <i>European Journal of Cancer</i> , 2014 , 50, 2050-6	7.5	50
117	Phase 1 trial design: is 3 + 3 the best?. <i>Cancer Control</i> , 2014 , 21, 200-8	2.2	47
116	Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma. <i>PLoS ONE</i> , 2014 , 9, e98557	7.7	10
115	A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. <i>Investigational New Drugs</i> , 2014 , 32, 1269-77	4.3	38
114	Genomic testing in cancer: patient knowledge, attitudes, and expectations. <i>Cancer</i> , 2014 , 120, 3066-73	6.4	58
113	Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. <i>European Journal of Human Genetics</i> , 2014 , 22, 391-5	5.3	79
112	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 1	22.4	104
111	A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3057-3057	2.2	1
110	A phase Ib combination study of R04929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013 , 31, 1182-91	4.3	45
109	Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4260-7	2.2	64
108	Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. <i>International Journal of Cancer</i> , 2013 , 132, 1547-55	7.5	73
107	Clinical genomics information management software linking cancer genome sequence and clinical decisions. <i>Genomics</i> , 2013 , 102, 140-7	4.3	13
106	Tumour heterogeneity in the clinic. <i>Nature</i> , 2013 , 501, 355-64	50.4	770

105	Designing transformative clinical trials in the cancer genome era. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1834-41	2.2	135
104	Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 543-50	2.2	454
103	Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2477-84	2.2	107
102	Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2919-28	2.2	160
101	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. <i>Radiotherapy and Oncology</i> , 2012 , 103, 49-56	5.3	142
100	Ocular toxicity of targeted therapies. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3277-86	2.2	95
99	Less than ideal: how oncologists practice with limited drug access. <i>Journal of Oncology Practice</i> , 2012 , 8, 190-5	3.1	8
98	A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012 , 35, 255-60	2.7	36
97	The utility of hedgehog signaling pathway inhibition for cancer. <i>Oncologist</i> , 2012 , 17, 1090-9	5.7	36
96	A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3082-3082	2.2	2
95	Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2504-2504	2.2	3
94	A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN-01). <i>Journal of Clinical Oncology</i> , 2012 , 30, 1865-1865	2.2	1
93	Important early advances in squamous cell carcinoma of the head and neck. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 373-6	7.1	1
92	Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC). <i>Journal of Clinical Oncology</i> , 2012 , 30, 2516-2516	2.2	
91	Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3027-3027	2.2	1
90	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2011 , 98, 15-22 ³	5.3	86
89	Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. <i>Journal of Clinical Oncology</i> , 2011 , 29, 934-43	2.2	239
88	A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2011 , 29, 996-1003	4.3	18

87	Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?. <i>BMC Cancer</i> , 2011 , 11, 426	4.8	21
86	Brivanib alaninate for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 577-86	5.9	35
85	Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 7539-50	12.9	75
84	Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-HodgkinB lymphomas. <i>Clinical Cancer Research</i> , 2011 , 17, 1582-90	12.9	81
83	Targeting the Hedgehog pathway in cancer: can the spines be smoothed?. <i>Clinical Cancer Research</i> , 2011 , 17, 2071-3	12.9	10
82	Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1401-7	2.2	43
81	Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. <i>Clinical Cancer Research</i> , 2010 , 16, 1726-36	12.9	126
80	Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1188-98	9.7	250
79	Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. <i>Clinical Cancer Research</i> , 2010 , 16, 4038-45	12.9	83
78	Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 751-60	6.1	16
77	Magnetic resonance imaging of nasopharyngeal carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 365-75	3.5	13
76	Reply to D.J. Stewart. <i>Journal of Clinical Oncology</i> , 2010 , 28, e651-e651	2.2	2
75	Molecular targeted therapies in all histologies of head and neck cancers: an update. <i>Current Opinion in Oncology</i> , 2010 , 22, 212-20	4.2	20
74	Randomized phase II trials: inevitable or inadvisable?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2641-7	2.2	61
73	Hepatic steatosis secondary to capecitabine: a case report. <i>Journal of Medical Case Reports</i> , 2010 , 4, 227	1.2	6
72	The contents and readability of informed consent forms for oncology clinical trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 387-92	2.7	20
71	Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 3177-83	12.9	92
70	Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5965-71	2.2	19

69	Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6213-21	2.2	255
68	Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. <i>Investigational New Drugs</i> , 2009 , 27, 586-94	4.3	50
67	Dose escalation methods in phase I cancer clinical trials. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 708-20	9.7	528
66	Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 191-6	3.8	22
65	Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. <i>Drug Resistance Updates</i> , 2008 , 11, 99-109	23.2	27
64	Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1324-30	2.2	19
63	Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1940-7	2.2	109
62	Improving the quality of abstract reporting for phase I cancer trials. <i>Clinical Cancer Research</i> , 2008 , 14, 1782-7	12.9	9
61	A phase I study of OGX-011, a 2Pmethoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 833-9	12.9	105
60	A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2008 , 14, 3450-5	12.9	167
59	Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. <i>Clinical Cancer Research</i> , 2008 , 14, 3441-9	12.9	77
58	Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1247-54	5.9	16
57	Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008 , 31, 64-70	2.7	43
56	Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. <i>Current Opinion in Oncology</i> , 2008 , 20, 256-63	4.2	44
55	Clinical trials and biomarker development with molecularly targeted agents and radiotherapy. <i>Cancer and Metastasis Reviews</i> , 2008 , 27, 339-49	9.6	6
54	Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , 2008 , 26, 257-64	4.3	67
53	A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. <i>Investigational New Drugs</i> , 2007 , 25, 217-25	4.3	22
52	The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. <i>Supportive Care in Cancer</i> , 2007 , 15, 829-40	3.9	30

51	Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3978-84	2.2	200
50	Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2184-90	2.2	83
49	Clinical trials in the elderly--a concept comes of age. <i>New England Journal of Medicine</i> , 2007 , 356, 1575-6	59.2	57
48	Molecularly targeted oncology therapeutics and prolongation of the QT interval. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3362-71	2.2	172
47	Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3766-73	2.2	188
46	Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2178-83	2.2	119
45	Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 4849-57	12.9	74
44	The influence of mentorship on research productivity in oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 549-55	2.7	7
43	Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. <i>BMC Cancer</i> , 2006 , 6, 263	4.8	46
42	Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. <i>International Journal of Cancer</i> , 2006 , 119, 2467-75	7.5	74
41	Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4801-7	2.2	87
40	Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 144-51	12.9	170
39	Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. <i>Clinical Cancer Research</i> , 2006 , 12, 2141-9	12.9	29
38	Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. <i>Anti-Cancer Drugs</i> , 2006 , 17, 81-7	2.4	3
37	. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> ,	2.7	
36	A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005 , 28, 547-54	2.7	14
35	Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005 , 814, 143-7	3.2	39
34	Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 56, 154-60	3.5	36

33	Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2005 , 23, 455-65	4.3	4
32	Analysis of treatment practices for elderly cancer patients in Ontario, Canada. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3802-10	2.2	94
31	Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6966-75	2.2	360
30	Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2332-8	2.2	258
29	A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 5526-33	12.9	85
28	Raf kinase as a target for anticancer therapeutics. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 677-85	6.1	221
27	Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6982-91	2.2	107
26	Development of molecular targeted anticancer agents: successes, failures and future directions. <i>Current Pharmaceutical Design</i> , 2005 , 11, 265-72	3.3	23
25	Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4410-7	2.2	58
24	Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. <i>Journal of Clinical Oncology</i> , 2004 , 22, 77-85	2.2	677
23	Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2760-76	2.2	115
22	Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4627-35	2.2	37
21	Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. <i>Investigational New Drugs</i> , 2003 , 21, 85-97	4.3	76
20	Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. <i>Supportive Care in Cancer</i> , 2003 , 11, 41-7	3.9	38
19	Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1618-23	2.2	258
18	The statins as anticancer agents. <i>Clinical Cancer Research</i> , 2003 , 9, 10-9	12.9	387
17	Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. <i>Clinical Cancer Research</i> , 2003 , 9, 2478-86	12.9	87
16	Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 2002 , 20, 96-109	2.2	30

15	Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2567-74	2.2	20
14	Rationale for Ras and raf-kinase as a target for cancer therapeutics. <i>Current Pharmaceutical Design</i> , 2002 , 8, 2231-42	3.3	34
13	A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2002 , 8, 2142-8	12.9	83
12	A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. <i>Clinical Cancer Research</i> , 2002 , 8, 2157-66	12.9	19
11	Impact of the media and the internet on oncology: survey of cancer patients and oncologists in Canada. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4291-7	2.2	192
10	Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3267-79	2.2	885
9	Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valsopodar in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3677-89	2.2	26
8	Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3974-85	2.2	12
7	Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , 2000 , 18, 4086-97	2.2	44
6	Telomerase: therapeutic potential in cancer. <i>Cancer Investigation</i> , 2000 , 18, 269-77	2.1	14
5	A phase II study of temozolomide in advanced untreated pancreatic cancer. <i>Investigational New Drugs</i> , 1998 , 16, 77-9	4.3	20
4	Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. <i>Investigational New Drugs</i> , 1998 , 16, 113-9	4.3	19
3	Use of mesna to prevent ifosfamide-induced urotoxicity. <i>Supportive Care in Cancer</i> , 1998 , 6, 144-54	3.9	34
2	A risk-benefit assessment of irinotecan in solid tumours. <i>Drug Safety</i> , 1998 , 18, 395-417	5.1	11
1	Vinblastine and erythromycin: an unrecognized serious drug interaction. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 35, 188-90	3.5	28